CiVi Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- CiVi Biopharma's estimated annual revenue is currently $2.3M per year.
- CiVi Biopharma's estimated revenue per employee is $155,000
Employee Data
- CiVi Biopharma has 15 Employees.
- CiVi Biopharma grew their employee count by 0% last year.
CiVi Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Development Officer | Reveal Email/Phone |
CiVi Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is CiVi Biopharma?
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi's innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Chevy Chase
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 15 | -74% | N/A |
#2 | $1.4M | 16 | 45% | N/A |
#3 | $1.5M | 17 | 0% | N/A |
#4 | $1.5M | 17 | 42% | N/A |
#5 | $3.5M | 20 | 11% | N/A |